BioCardia (BCDA) CEO Peter Altman Buys Stock

What Happened

• Peter Altman, President, CEO and Director of BioCardia, acquired 1,900 shares in an open-market purchase on August 13, 2026. The filing reports a weighted-average price of $0.92 per share for a total cost of approximately $1,748. This was a purchase (buy), which is generally treated by investors as a more bullish signal than a sale.

Key Details

• Transaction date: 2026-08-13.
• Transaction type: Open-market purchase (Code P).
• Shares purchased: 1,900; weighted-average price: $0.92; total value: ~$1,748.
• Price range: Executed in multiple trades at prices between $0.89 and $0.95 per share (footnote F1); the filing uses the weighted average and offers to provide trade-by-trade details on request.
• Shares owned after transaction: Not specified in the excerpt of the filing provided.
• Timeliness: Reported same day (Period of Report = filing date), indicating a timely Form 4.

Context

• This was a straightforward open-market purchase, not an option exercise, gift, or award. The dollar amount is small relative to many insider transactions, so while it indicates a direct purchase by the CEO, investors should view it in context with other insider activity and company developments.
• No 10b5-1 plan, tax-withholding, or other special reporting notes were indicated in the provided filing excerpt.